Skip to main content

Advertisement

SpringerLink
Log in

Five-year potency preservation after iodine-125 prostate brachytherapy

  • Original Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Background

We aimed to evaluate long-term erectile function following prostate brachytherapy, based on patient characteristics and treatment factors.

Methods

Between 2003 and 2006, 665 men with localized prostate cancer were treated with 125I permanent seed implantation. None was given adjuvant hormone therapy. Erectile function was assessed before treatment, and at 6 months, 1, 2, 3, 4 and 5 years after implantation using the Mount Sinai Erectile Function Score (MSEFS) of 0–3 (0 = no erections, 1 = erections insufficient for intercourse, 2 = suboptimal erections but sufficient for intercourse, 3 = normal erectile function). Potency was defined as score 2 or 3, and 382 men were potent before treatment. Univariate and multivariate analyses were performed on the data from these 382 patients to identify variables associated with potency preservation.

Results

In patients who were potent before treatment, the actuarial potency preservation rate fell to 46.2 % at 6 months after brachytherapy, and then slowly recovered reaching 52.0 % at 5 years after brachytherapy. In multivariate logistic regression analysis, patient age (p = 0.04) and pre-treatment MSEFS (p < 0.001) were predictors of 5-year potency preservation. Neoadjuvant hormone therapy affected potency preservation only at 6 months after brachytherapy.

Conclusions

Patient age at implantation and pre-treatment erectile function are predictive factors for the development of erectile dysfunction following prostate brachytherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Kupelian PA, Potters L, Khuntia D et al (2004) Radical prostatectomy, external beam radiotherapy < 72 Gy, external beam radiotherapy ≥72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1–T2 prostate cancer. Int J Radiat Oncol Biol Phys 58:25–33

    Article  PubMed  Google Scholar 

  2. Peschel RE, Colberg JW (2003) Surgery, brachytherapy, and external-beam radiotherapy for early prostate cancer. Lancet Oncol 4:233–241

    Article  PubMed  Google Scholar 

  3. Sanda MG, Dunn RL, Michalski J et al (2008) Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 358:1250–1261

    Article  PubMed  CAS  Google Scholar 

  4. Robinson JW, Moritz S, Fung T (2002) Meta-analysis of rates of erectile function after treatment of localized prostate carcinoma. Int J Radiat Oncol Biol Phys 54:1063–1068

    Article  PubMed  Google Scholar 

  5. Crook JM, Gomez-Iturriaga A, Wallace K et al (2011) Comparison of health-related quality of life 5 years after SPIRIT: surgical prostatectomy versus interstitial radiation intervention trial. J Clin Oncol 29:362–368

    Article  PubMed  Google Scholar 

  6. Alemozaffar M, Regan MM, Cooperberg MR et al (2011) Prediction of erectile function following treatment for prostate cancer. JAMA 306:1205–1214

    Article  PubMed  CAS  Google Scholar 

  7. Zelefsky MJ, Hollister T, Raben A et al (2000) Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys 47:1261–1266

    Article  PubMed  CAS  Google Scholar 

  8. Stone NN, Stock RG (2007) Long-term urinary, sexual, and rectal morbidity in patients treated with iodine-125 prostate brachytherapy followed up for a minimum of 5 years. Urology 69:338–342

    Article  PubMed  Google Scholar 

  9. Merrick GS, Butler WM, Wallner KE et al (2005) Erectile function after prostate brachytherapy. Int J Radiat Oncol Biol Phys 62:437–447

    Article  PubMed  Google Scholar 

  10. Cancer Registration Committee of the Japanese Urological A (2005) Clinicopathological statistics on registered prostate cancer patients in Japan: 2000 report from the Japanese Urological Association. Int J Urol 12:46–61

    Article  Google Scholar 

  11. Ohashi T, Yorozu A, Toya K et al (2005) Acute urinary morbidity following I-125 prostate brachytherapy. Int J Clin Oncol 10:262–268

    Article  PubMed  Google Scholar 

  12. Ohashi T, Yorozu A, Toya K et al (2007) Rectal morbidity following I-125 prostate brachytherapy in relation to dosimetry. Jpn J Clin Oncol 37:121–126

    Article  PubMed  Google Scholar 

  13. Yoshida K, Ohashi T, Yorozu A et al (2013) Comparison of preplanning and intraoperative planning for I-125 prostate brachytherapy. Jpn J Clin Oncol 43:383–389

    Article  PubMed  Google Scholar 

  14. Stock RG, Stone NN, Cesaretti JA et al (2006) Biologically effective dose values for prostate brachytherapy: effects on PSA failure and posttreatment biopsy results. Int J Radiat Oncol Biol Phys 64:527–533

    Article  PubMed  Google Scholar 

  15. Stock RG, Kao J, Stone NN (2001) Penile erectile function after permanent radioactive seed implantation for treatment of prostate cancer. J Urol 165:436–439

    Article  PubMed  CAS  Google Scholar 

  16. Zagar TM, Stock RG, Cesaretti JA et al (2007) Assessment of postbrachytherapy sexual function: a comparison of the IIEF-5 and the MSEFS. Brachytherapy 6:26–33

    Article  PubMed  Google Scholar 

  17. Taira AV, Merrick GS, Galbreath RW et al (2009) Erectile function durability following permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 75:639–648

    Article  PubMed  Google Scholar 

  18. Potters L, Torre T, Fearn PA et al (2001) Potency after permanent prostate brachytherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 50:1235–1242

    Article  PubMed  CAS  Google Scholar 

  19. Snyder KM, Stock RG, Buckstein M et al (2012) Long-term potency preservation following brachytherapy for prostate cancer. BJU Int 110:221–225

    Article  PubMed  Google Scholar 

  20. Kollmeier MA, Fidaleo A, Pei X et al (2013) Favourable long-term outcomes with brachytherapy-based regimens in men ≤60 years with clinically localized prostate cancer. BJU Int 111:1231–1236

    Article  PubMed  Google Scholar 

  21. Zelefsky MJ, McKee AB, Lee H et al (1999) Efficacy of oral sildenafil in patients with erectile dysfunction after radiotherapy for carcinoma of the prostate. Urology 53:775–778

    Article  PubMed  CAS  Google Scholar 

  22. Bannowsky A, Schulze H, van der Horst C et al (2008) Recovery of erectile function after nerve-sparing radical prostatectomy: improvement with nightly low-dose sildenafil. BJU Int 101:1279–1283

    Article  PubMed  CAS  Google Scholar 

  23. Pahlajani G, Raina R, Jones JS et al (2010) Early intervention with phosphodiesterase-5 inhibitors after prostate brachytherapy improves subsequent erectile function. BJU Int 106:1524–1527

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The authors are grateful to Ms. Kazuko Ogawa at Keio University School of Medicine for her support and assistance.

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Radiology, National Hospital Organization Tokyo Medical Center, 2-5-1 Higashigaoka, Meguro-ku, Tokyo, 152-8902, Japan

    Shuichi Nishimura, Atsunori Yorozu, Masanori Sakayori, Kayo Yoshida & Kazuhito Toya

  2. Department of Radiology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan

    Toshio Ohashi, Yutaka Shiraishi & Naoyuki Shigematsu

  3. Department of Urology, National Hospital Organization Tokyo Medical Center, 2-5-1 Higashigaoka, Meguro-ku, Tokyo, 152-8902, Japan

    Yasuto Yagi, Toru Nishiyama & Shiro Saito

Authors
  1. Shuichi Nishimura
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Atsunori Yorozu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Toshio Ohashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Masanori Sakayori
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yasuto Yagi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Toru Nishiyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Shiro Saito
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yutaka Shiraishi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Kayo Yoshida
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Kazuhito Toya
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Naoyuki Shigematsu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Toshio Ohashi.

About this article

Cite this article

Nishimura, S., Yorozu, A., Ohashi, T. et al. Five-year potency preservation after iodine-125 prostate brachytherapy. Int J Clin Oncol 19, 940–945 (2014). https://doi.org/10.1007/s10147-013-0632-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-013-0632-8

Keywords

Search

Navigation